摘要
目的比较安罗替尼(AL)联合贝伐珠单抗(BEVA)治疗晚期表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)获得性耐药肺腺癌(LUAD)的疗效和安全性。方法回顾性分析2022年1月至2023年1月宜宾市第三人民医院肿瘤科接受治疗的EGFR-TKI获得性耐药LUAD患者临床资料。根据治疗方案,将患者分为BEVA组和AL组。两组患者在标准化疗方案的基础上,联用BEVA注射液或AL胶囊,共治疗4个周期。主要观察指标包括肿瘤标志物[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和血管内皮生长因子(VEGF)]水平变化、近期临床疗效[总缓解率(ORR)和疾病控制率(DCR)]、无进展生存期(PFS)、1年生存率和药物相关不良反应。结果研究共纳入60名EGFR-TKI获得性耐药LUAD患者,BEVA组32例,AL组28例。治疗4个周期后,两组患者血清CEA、NSE和VEGF水平均显著降低,且AL组低于BEVA组(P<0.05)两组患者完全缓解比例、部分缓解比例、疾病稳定比例和ORR之间差异无统计学意义(P>0.05)。与BEVA组相比,AL组患者出现疾病进展比例较低(P<0.05),而DCR较高(P<0.05)。此外,BEVA组中位PFS较AL组显著延长(8.4vs.7.2个月,P<0.05),而两组生存率比较差异无统计学意义(P>0.05)。在不良反应方面,AL组患者恶心呕吐发生率较低,而骨髓抑制发生率较高,总体不良反应等级较低。结论相较于BEVA联合化疗方案,AL联合化疗在治疗EGFR-TKI耐药晚期LUAD方面显示出更好的疗效,且安全性良好。
Objective To compare the efficacy and safety of anlotinib(AL)and bevacizumab(BEVA)in the treatment of advanced lung adenocarcinoma(LUAD)with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKI).Methods The clinical data of patients with EGFR-TKI-resistant LUAD who were treated in the Department of Oncology of Yibin Third People's Hospital from January 2022 to January 2023 were retrospectively analyzed.According to the treatment plan,patients were divided into BEVA group and AL group.Both groups were treated with BEVA injection or AL capsule in combination with standard chemotherapy for a total of 4 cycles.The main outcome measures included changes in tumor marker levels[carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),and vascular endothelial growth factor(VEGF)],recent clinical efficacy[overall response rate(ORR)and disease control rate(DCR)],progressionfree survival(PFS),1-year survival rate,and drug-related adverse reactions.Results A total of 60 patients with EGFR-TKI-resistant LUAD were included in the study,including 32 patients in the BEVA group and 28 patients in the AL group.After four cycles of treatment,the levels of serum CEA,NSE,and VEGF in both groups significantly decreased,and AL group was lower than BEVA group(P<0.05).There were no significant statistical differences in the complete remission rate,partial remission rate,disease stability rate,and ORR between the two groups(P>0.05).Compared with the BEVA group,the AL group had a lower rate of disease progression(P<0.05)and a higher DCR(P<0.05).In addition,the median PFS in the BEVA group was significantly longer than that in the AL group(8.4 vs.7.2 months,P<0.05),while there was no significant difference in survival rate between the two groups(P>0.05).In terms of adverse reactions,patients in the AL group had a lower incidence of nausea and vomiting,but a higher incidence of bone marrow suppression,resulting in a lower overall adverse reaction grade.Conclusion Compared with the BEVA combination chemotherapy regimen,AL combination chemotherapy showed better efficacy and good safety in the treatment of EGFRTKI-resistant advanced LUAD.
作者
熊菊方
郭星宇
周美英
XIONG Jufang;GUO Xingyu;ZHOU Meiying(Department of Oncology,The Third People's Hospital of Yibin,Yibin 644000,Sichuan Province,China)
出处
《中国药师》
CAS
2024年第7期1162-1169,共8页
China Pharmacist
基金
成都市医学科研课题项目(2020156)。